Affiliate disclosure: The RX Index may earn a commission from some links on this page. We may earn a commission if you use a tracked Oak link on this page. We are not Oak's medical provider. Commissions never change our scoring, what we report, or what you pay.

By The RX Index Editorial Desk · Last verified: August 27, 2026 · Next re-verification: September 1, 2026

Oak GLP-1 Reviews (2026): What Oak Weight Loss Program Really Costs

Oak is a functioning cash-pay telehealth platform. But its own live pages showed three different starting prices on August 27, 2026: $119, $167, and $190. Trustpilot showed 54 reviews, not the 75,000 one review site claims. Oak's weight-loss products are compounded medications, not FDA-approved drugs. Most prescriptions can renew, the price can change with the dose, and Oak's stated refund window closes after approval and pharmacy transfer. For a cash-pay weekly compounded injection, Oak can be competitive when you verify the final cart. For a fixed public price, an FDA-approved product, or insurance billing, start somewhere else.

Here's the thing almost nobody looking at Oak GLP-1 reviews has noticed. Oak's own comparison chart says brand-name medications cost "$1,000–$1,400 a month." That is a list-price frame, not the current manufacturer cash price. The FDA-approved Wegovy pill starts at $149 a month, but the FDA label steps up to doses that NovoCare prices at $299 a month. Zepbound starts at $299 a month through LillyDirect.

Which means the honest answer is more useful than the easy one: Oak may be cheaper for a weekly compounded injection, but the $149 Wegovy pill is not a $149-for-the-whole-year treatment.

We'll show you the math in a minute. First, the fast version.

Oak at a glance

Every row above is sourced further down. Verified August 27, 2026.

What Oak says versus what we could verify

Oak might fit you — or it might not

Oak may be worth your time if:

• You're paying cash and price is your biggest concern
• You want the weekly injection and you're comfortable with a compounded medication
• You want an online form instead of a required video call
• You don't mind doing a little verification before you pay

Look somewhere else if:

• You want an FDA-approved pill with a published dose-by-dose price
• You want to use insurance, Medicare, or Medicaid through the provider
• You want a brand-name drug like Wegovy, Zepbound, Ozempic, or Mounjaro
• You need to know your exact price for the next 12 months before you commit
• You want a broad refund window after you order

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose. Get your personalized GLP-1 match in 60 seconds →

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Before you read another word: here's how we make money

We're going to say some pointed things about Oak on this page. So you should know exactly what's in it for us.

We're an affiliate site. If you click through to certain providers and sign up, we get paid. We don't get paid a cent if you sign up with Oak. We're not their partner. We never have been.

That cuts both ways, so please check us. Every current price on this page points to the company's own page. Trustpilot takes one tap. Oak's terms are public and free to read. If our math is wrong, you'll spot it in about ninety seconds — and we'd rather you did than take our word for it.

What we actually verified

We checked these ourselves on August 27, 2026:

• ✅ Oak's homepage, weight-loss page, and older live home page — all three, in full
• ✅ Both complete sets of Oak's Terms of Use that are stacked on the same URL
• ✅ Oak's privacy policy
• ✅ Oak's public Trustpilot profile — including the review count, score, star split, recent-review count, and company-activity summary
• ✅ Oak's Better Business Bureau listing
• ✅ Current Wegovy pricing through NovoCare and the FDA-approved tablet dosing schedule
• ✅ Current Zepbound self-pay pricing through LillyDirect
• ✅ The FDA's current compounded GLP-1 safety page, shortage updates, marketing-enforcement notices, and 503A guidance
• ✅ The Federal Register record for the pending 503B bulk-substance proposal
• ✅ The review page making the 75,000-review claim

We did NOT do these, and we won't pretend otherwise:

• ❌ Buy medication from Oak
• ❌ Test what's in a vial
• ❌ Complete a cancellation or a refund
• ❌ Time their shipping or their support
• ❌ Receive medical care through Oak
• ❌ Confirm which pharmacy would fill a specific reader's prescription

Anything we couldn't confirm, we say so in plain English on this page. No guessing dressed up as fact.

Is the Oak Weight Loss Program legit?

Oak Longevity is a functioning telehealth platform, not an anonymous storefront. It publishes terms, lists a working phone number, has a BBB business profile, names a contracted medical group in checkout material, and names a preferred pharmacy. But “real company” doesn't mean the medication is FDA-approved, the price is what you saw in the ad, or that a refund is available after you order.

Let's separate two things people mash together.

“Is it a scam?” We found no sign of an anonymous fake storefront. There's a real business here with a real process.

“Is it a good deal for me?” That depends on five things — and Oak's public pages don't answer all five clearly.

How Oak actually works

Oak isn't your doctor. Its own terms say so, in capital letters: “OAK DOES NOT PROVIDE HEALTHCARE SERVICES.”

Four separate parties are involved:

Oak's job is the platform. The medical decision belongs to a clinician you may never speak to on the phone. The medication comes from a pharmacy Oak doesn't name on its public marketing pages.

That's not unusual for telehealth. It just means “Oak approved me” isn't quite the right way to think about it. A clinician approved you. Oak handled the checkout.

What being “legit” doesn't prove

Being a real operating business doesn't prove:

• The medication is right for you
• The price you saw is the price you'll pay
• The same pharmacy fills every order
• The product is FDA-approved — it isn't
• You can get your money back after approval
• Your state and selected product are covered
• Anyone's results are typical

Our verdict on legitimacy: Oak looks like a functioning cash-pay telehealth platform. The part we wouldn't skip is the last mile — the exact prescriber, the exact pharmacy, the exact product, the exact total, and the exact refund cutoff.

We'll walk you through every one of those.

Oak GLP-1 reviews: what do Trustpilot reviewers actually say?

Oak's Trustpilot profile showed 54 reviews on August 27, 2026. The page displayed a 4.4 consumer score and a TrustScore graphic of 4.5 out of 5, with 89% five-star and 5% one-star. Only 11 reviews were posted in the previous 12 months. That's a small sample — and it's roughly 1,400 times smaller than what one review site currently ranking for this search claims Oak has.

This is a reviews search, so let's start here.

The 75,000 problem

One of the pages ranking right now for “Oak GLP-1 reviews” says this:

“More than 75,000 verified member reviews.”

It puts that number under a Trustpilot star graphic labeled “Trustpilot · Verified Reviews.”

We opened Trustpilot. 54 reviews. Displayed score 4.4. TrustScore graphic 4.5.

Do the arithmetic. The claimed number is about 1,389 times the Trustpilot count. And here's the part that really settles it: Trustpilot's own profile shows 11 reviews in the previous 12 months. At that pace, collecting 75,000 reviews would take roughly 6,800 years.

That same page lists nine glowing testimonials from people labeled “Verified Members,” each with an exact pound count. Those testimonials are presented by that review page, not as Trustpilot's review corpus, and the page does not show how it verified them.

It also says Oak is available in all 50 U.S. states. Oak's older live Terms of Use say 45, while the newer terms say only “certain states.”

It also presents Wegovy and Zepbound as Oak options. Oak's current weight-loss page presents compounded GLP-1/GIP, compounded GLP-1, and oral or peptide options — not those brand-name drugs.

And in its “How We Researched and Rated” section, it scores Oak across eight categories. Every category gets five stars. It then reports an overall rating of 4.8. Eight fives don't average 4.8.

We're not naming that site to pick a fight. We're naming the claim because you can check it yourself in one tap, and because when you're about to spend thousands of dollars a year on a medication, you deserve to know which numbers are real.

The FTC's Rule on the Use of Consumer Reviews and Testimonials — 16 CFR Part 465, effective October 21, 2024 — covers fake, false, and misrepresented consumer reviews and testimonials. We are not making a legal finding about that page. We are showing you a checkable mismatch.

What Oak's own numbers say

To be fair, Oak's own counting isn't perfectly consistent either.

Two different customer counts on one page, off by double. Those are marketing figures, not review counts — but if you're trying to gauge how big this company is, you can see the problem.

Here's what Oak genuinely deserves credit for

Every Trustpilot review we checked was labeled “Unprompted review.” Trustpilot also says the company has no recent history of asking for reviews. That means the current Trustpilot sample was not recently built through Trustpilot invitations.

Trustpilot's current company-activity summary says “Hasn't replied to negative reviews.” Oak has visible replies on some older reviews, including the warm-shipment complaint below, so the accurate claim is simple: Oak has replied to some reviews, not all negative reviews.

The 75,000 claim isn't Oak's. It's on a third-party page trying to earn a commission.

What individual reviewers actually said

These are comments from Oak's public Trustpilot profile. Individual experiences. Not typical results, not proof of medical effectiveness, and not identities, orders, or outcomes we independently verified.

⭐⭐⭐⭐⭐ August 5, 2025 — and this one matters:

“Through all of my titrations, the price has only gone up from $190 to $229.”

That's a happy customer. Five stars. And she just told you one of the most useful things on this entire page: her price went up as her dose went up. Oak's own terms say subscription fees may change with dosage, prescription, or product form.

⭐⭐⭐⭐⭐ October 1, 2025 — “Cindy”:

“The support staff helped me kindly… The doctors have been available for questions.”

She also reported losing 15 pounds over four months. That is one person's report, not a promised or typical result.

⭐⭐⭐ June 1, 2025 — “Phil”:

“Customer service is a little disconnected from the actual product… and the prescribing physician.”

He said that separation could delay answers.

⭐ August 12, 2025 — “Mesue Babcock”:

“I took a day off work… AGAIN NOTHING WAS DELIVERED.”

That last one deserves attention. FDA says injectable GLP-1 drugs need refrigeration as their labels direct, and it has received complaints that compounded GLP-1 drugs arrived warm or with too little ice.

To Oak's credit, it replied publicly to that review and said refunds had already been issued. But if you order, track the package. If an injectable drug arrives warm or without enough refrigeration, do not use it until the dispensing pharmacy or prescriber tells you what to do. Photograph the box, ice packs, label, and delivery time.

One more thing customers mention: several reviewers said Oak did not include anti-nausea medication. Nausea is a common GLP-1 side effect, but do not assume you need or will receive another prescription. Ask the prescriber how side effects are handled before you order.

These comments reflect individual Trustpilot reviewers. We did not verify their medical histories, orders, outcomes, or identities. Experiences and results vary.

How much does Oak GLP-1 cost in 2026?

Oak's own live website published three different starting-price claims on August 27, 2026: $119, $167, and $190. The $119 claim may cover Oak's broader catalog, not GLP-1 treatment. Oak's terms also say the subscription fee can change with the dose, prescription, or product form. The only number that belongs to you is the complete charge on your final cart.

This is our proprietary price record. It didn't exist anywhere before we built it.

The live Oak price ladder

Three different starting-price claims are live on Oak's own website. We checked all three pages on the same day.

Older checkout walkthroughs and affiliate pages show still more numbers. We are not presenting those as current Oak prices because we did not reproduce them in a live Oak cart on August 27. That is exactly how stale price claims spread.

Why so many numbers?

We want to be fair here, because there are legitimate reasons prices differ:

• Different landing pages and promotional offers
• One month versus a multi-month prepay
• Promotional pricing versus the renewal rate
• Different medications and formulations
• Different doses
• An old page that never got updated

And one more honest caveat: the homepage's $119 says “programs,” plural. Oak sells things besides GLP-1s, including NAD+, tadalafil, sermorelin, and glutathione. It's possible $119 is the cheapest program in the full catalog, not the cheapest GLP-1. We'd rather tell you that than pretend the headline proves more than it does.

But here's what none of those explanations fix: Oak does not publish one clean, dose-by-dose GLP-1 price list that lets you map the first charge, refill charge, and higher-dose charge before you begin.

The one rule we'd give anyone considering Oak

Get all the way to the final checkout screen — with your medication, form, dose, and plan length selected — before you enter a card. Then screenshot it. Screenshot the amount due today, how many weeks it covers, the next charge date, the renewal amount, whether the dose changes that amount, and the cancellation language. That screenshot is the only price that's actually yours.

🔴 The one thing that gives us pause

Here it is, plainly, because you deserve it before any button:

Oak does not publish one clear, stable GLP-1 price. If knowing exactly what you'll pay for the next twelve months is your top priority, a program with a public dose-by-dose price list is easier to trust and budget for.

But here's the flip side. Oak is plainly trying to compete on low cash-pay entry prices. Its weight-loss page markets free shipping, free care-team access, and “no hidden membership fees.” That can make the final bundle competitive.

The damaging admission is that the terms do not let us simply repeat “no membership fee” as a clean fact. An older set of terms still live on Oak's site says checkout includes a membership fee for the provider consult. The same terms say the fee can change with dose or product. The final all-in cart matters more than the label Oak puts on each piece of the charge.

So the tradeoff is real. You may get a low starting price. You give up public price certainty.

One screenshot at checkout will not lock the price for a year, but it will prove what Oak showed you before the first charge.

See Oak's current options and save your final checkout screen → (tracked Oak link — we may earn a commission)

Prescription required. Approval is not guaranteed. Confirm the amount due today, supply length, next charge date, dose-based price changes, and refund cutoff before you pay.

Is Oak actually cheaper than Wegovy or Zepbound?

Sometimes — but the easy $149 × 12 comparison is wrong. The FDA-approved Wegovy pill starts at $149, then the labeled dose steps to 4 mg, 9 mg, and a recommended 25 mg maintenance dose. NovoCare prices those doses at $149, $199, $299, and $299. A standard labeled first year is about $3,338, not $1,788. Oak can still be cheaper under a flat-price example, but the answer depends on the form, dose, refill timing, and whether Oak's price rises.

We verified every manufacturer number below on August 27, 2026.

What FDA-approved drugs actually cost cash payers

⏰ One date to know: Novo Nordisk says the temporary $149 price for the 4 mg Wegovy tablet ends August 31, 2026. The standard 4 mg price is $199. The 1.5 mg dose remains $149 under the current program, while 9 mg and 25 mg are $299.

Head to head

These are not equivalent products. A lower price does not prove equal quality, dosing, clinical effect, or regulatory protection.

The corrected 12-month math

Wegovy pill, standard published prices:

• Month 1 at 1.5 mg: $149
• Month 2 at 4 mg: $199
• Month 3 at 9 mg: $299
• Months 4–12 at 25 mg: $299 × 9 = $2,691
• Standard first-year total: $3,338

If the 4 mg fill qualifies for the temporary $149 offer before August 31, the first-year total would be $3,288 instead.

Oak examples, only if the monthly price stayed flat:

• Oak at $190/month = $2,280 a year
• Oak at $229/month = $2,748 a year

Under those exact flat-price assumptions, Oak would cost $590 to $1,058 less than the standard Wegovy pill price path. But Oak's terms allow dose-based price changes, and Oak's oral product is not the FDA-approved Wegovy tablet. Treat this as budget math, not a claim of equivalence.

Wegovy pen example for a new patient eligible for the current offer:

• $199 + $199 + ($349 × 10) = $3,888 for 12 monthly fills
• Compared with Oak at a flat $190/month: $1,608 less for Oak
• Compared with Oak at a flat $229/month: $1,140 less for Oak

Again, the Oak side is an example. Your cart may be different, and the price may rise with the dose.

We are not giving a single 12-month Zepbound-versus-Oak number because that would pretend to know your maintenance dose, whether every refill lands within Lilly's 45-day window, and what Oak will charge at each tirzepatide dose. The public evidence does not support one honest number.

So what do you do with that?

For a pill: compare the FDA-approved Wegovy pill with Oak's exact oral cart. Wegovy starts at $149, but do not mistake the starter price for the full-year price. Its standard labeled first-year cash cost is about $3,338 under the current published schedule.

For the weekly shot while paying cash: Oak can be genuinely cheaper than the current manufacturer cash price. That's not a promise. It's what the public starting price and a documented customer price suggest. Your final cart decides it.

If you might have insurance coverage: find out before you pay cash for anything. Eligible commercially insured patients with coverage may pay as little as $25 under manufacturer savings terms, but that is not a guaranteed price and program limits apply. Medicare and Medicaid eligibility follows different rules.

Ro offers a free coverage checker for the Ozempic pen, Wegovy pen, and Zepbound pen. It contacts your insurer and tells you whether prior authorization is required. It does not prescribe medication or submit a treatment request through the free checker. If you later enroll in Ro's program, Ro charges a membership — $39 for the first month, then $74 to $149 a month depending on the plan — and medication costs extra.

Check your GLP-1 insurance coverage free →

Being straight with you about the tradeoff: Oak does not bill insurance. A service like Ro costs more for care access, but it may help you find and use coverage. If you are certain you have no coverage and only want a cash-pay compounded injection, Oak may still come out ahead. If you have coverage, paying cash before checking it can be the most expensive choice on the page.

Is Oak a subscription? Can you cancel and get a refund?

Some Oak checkout material says “No Subscriptions.” Oak's Terms of Use say most prescriptions are set to renew and charge the card on file until you cancel. The fairest reading: Oak may not sell a separate public access subscription on every offer, while the medication refill itself can still recur. Oak's stated refund window closes after a clinician approves the treatment and sends the order to the pharmacy or fulfillment partner.

This is where careful reading pays for itself.

The four things people mix up

“No hidden membership fee” and “no recurring charge” are not the same sentence. And because Oak's marketing and older terms use the word membership differently, the safe move is to judge the complete cart, not the label.

What Oak's terms actually say

Straight from the document published on Oak's site:

On renewal:

“Most of these prescriptions are configured as a subscription that will renew on a recurring basis.”

Oak says it will charge the form of payment on file and continue until a listed stopping event occurs, including canceling the prescription or deleting the account.

On price changes:

“Your Subscription fee may change from time to time based on changes in dosage, prescription or form of product.”

That line is the contract version of what the Trustpilot reviewer described — $190 to $229 as her dose climbed.

On the consult fee:

Oak's older live terms say checkout includes a membership fee for the provider consult and list $40 for a synchronous video visit and $20 for an asynchronous review as the provider's contracted portion.

This does not tell us Oak's margin or the pharmacy's cost. It does prove the live terms are not as simple as “there is no membership fee at all.”

On refunds:

Once a provider has approved and prescribed the treatment and the order has been sent to the pharmacy or fulfillment partner, Oak says the order cannot be canceled and is non-refundable — even if the customer tries to stop, hold, reroute, return, or cancel the shipment.

On cancellation timing:

Oak says cancellation is handled on a best-efforts basis, with a goal of 24 hours. Paid refills and orders within 48 hours of shipment may still be sent.

Your cancellation timeline, in plain English

The critical thing: your window can close at approval and pharmacy transfer, not when the box ships. Oak advertises fast review. If you have doubts, don't submit and then think it over. Think it over first.

Three other things buried in the terms

Oak says it is not a HIPAA covered entity. In its older live terms, Oak says it does not fall under HIPAA as a covered entity. Clinicians and pharmacies may have their own HIPAA duties. This is Oak's legal position in its terms, not our independent legal ruling.

Your medication will not arrive in child-resistant packaging if you use the Oak Pharmacy Network. The newer terms say that directly and tell customers to keep it out of children's reach. If you have kids at home, plan a locked or unreachable storage spot before the box arrives. Follow the dispensing label for refrigeration.

Disputes go to arbitration. The newer terms require binding individual arbitration in New York and waive class proceedings. The older terms also contain a prevailing-party legal-fee clause. Read the version shown when you order because both sets remain on the same page.

How to cancel cleanly

1. Log in before your next charge date.
2. Cancel the prescription, not just marketing emails.
3. Screenshot the confirmation with the date and time.
4. Message support and ask: “Is any approved or pending pharmacy order still active?”
5. Save that reply.
6. Ask whether deleting the account is also required to stop every charge.
7. Check your card statement on the next cycle.
8. If you're stopping the medication itself, talk to the prescriber separately.

Read Oak's current terms before you submit an order → (tracked Oak link — we may earn a commission)

Not comfortable with that refund window? That's a completely reasonable place to draw a line. Take our free matching quiz and we'll show you treatment paths whose billing and cancellation setup better fits what you're comfortable with. Find your GLP-1 path in 60 seconds →

Who prescribes Oak's medication, and which pharmacy fills it?

Oak's checkout material names NVP Medical Group as a contracted medical group and InnovaScript Pharmacy as a preferred pharmacy. Neither is named on Oak's public weight-loss marketing page. Oak's terms also describe a broader “Oak Pharmacy Network,” which means a preferred pharmacy is not necessarily the pharmacy that fills your specific order.

This matters more than people realize. When a medication isn't FDA-approved, the exact pharmacy, label, concentration, and instructions are some of the most important checks you have.

What Oak does and doesn't tell you upfront

Oak's homepage and weight-loss page say “licensed U.S. compounding pharmacies” and “obesity-certified doctors.” They don't name a single doctor or a single pharmacy on those marketing pages.

You have to reach checkout material to see names. That's where NVP Medical Group and InnovaScript Pharmacy appear.

Oak's terms then say prescriptions may be filled through the “Oak Pharmacy Network.” So a preferred pharmacy is a preference — not proof that it made your vial.

Oak also does not say on its public weight-loss page whether the actual compounder for your order is a 503A pharmacy or a 503B outsourcing facility.

• A 503A pharmacy compounds for an identified patient under a prescription and state-board oversight, subject to federal conditions.
• A 503B outsourcing facility registers with FDA and can compound larger batches under a different federal framework.

That distinction changes the rules and oversight, but it does not answer everything by itself. A 503A or 503B label does not make the compounded finished drug FDA-approved. “FDA-registered pharmacy” also does not mean FDA approved the medication.

The five questions to ask before you pay

Message support and ask these. Save the answer.

1. Which pharmacy will actually fill my prescription?
2. Is it a state-licensed 503A pharmacy, an FDA-registered 503B outsourcing facility, or dispensing an FDA-approved product?
3. What is my prescriber's full name and state license number?
4. What is the pharmacy's phone number and state license information?
5. What exact medication, base or salt form, concentration in mg/mL, dose in mg, syringe units, and instructions will be on the label?

Then verify the pharmacy yourself. The FDA's BeSafeRx program recommends checking that an online pharmacy appears in your state board's database, requires a prescription, lists a U.S. address, and has a licensed pharmacist you can reach.

This takes about ten minutes. It's the cheapest insurance you'll ever buy.

Are Oak's compounded GLP-1 medications FDA-approved?

No. Compounded medications are not FDA-approved finished drug products. FDA does not review them for safety, effectiveness, or quality before they are marketed. Compounded drugs can meet a real patient need when a licensed clinician and lawful compounder follow the rules — but they are not approved generics and are not FDA-approved versions of Wegovy, Ozempic, Zepbound, or Mounjaro.

Here's what “compounded” means in plain words: a pharmacy makes a medication for a patient under a prescription. It does not go through the same FDA approval process as a brand-name drug.

That's not automatically bad. It's just a different thing with a different set of protections.

A marketing issue worth knowing about

Oak's live website says its compounded products “contain the same active ingredient as their brand-name counterparts,” that “the core therapeutic molecule is identical,” and that they are “designed to support the same clinical outcomes.” An older Oak page describes “clinically-proven results.”

FDA has drawn a bright line around that language. On February 6, 2026, FDA said companies cannot market non-FDA-approved compounded GLP-1 products as generic versions of, the same as, or clinically proven to match FDA-approved drugs. On March 3, 2026, FDA announced warning letters to 30 telehealth companies, with common problems including implied sameness and obscuring the source of claims.

We want to be precise about this: we found no FDA warning letter to Oak, and we are not saying FDA has taken action against Oak. We're telling you that Oak uses the same types of equivalence claims FDA has told telehealth companies not to make. Do not lean on “same” or “identical” language when you decide.

What FDA says you should know

From FDA's current guidance on unapproved GLP-1 drugs:

• Compounded versions do not go through FDA review for safety, effectiveness, or quality before marketing.
• FDA says compounded drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug.
• Some semaglutide sold by compounders may use semaglutide sodium or semaglutide acetate. FDA says those salt forms are different active ingredients from the semaglutide base used in approved drugs and that it is not aware of a lawful basis for their use in compounding.
• FDA has received reports of dosing errors with compounded injectable semaglutide, some serious enough to require medical care or hospitalization. Concentrations and syringe-unit instructions can vary.
• FDA has received complaints that compounded injectable GLP-1 drugs arrived warm or with too little refrigeration.
• FDA has identified fraudulent compounded products with false or misleading labels, including labels naming pharmacies that did not make the drug.
• As of May 31, 2026, FDA had received 990 adverse-event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide — more than 1,720 combined reports.

That last number needs context. An adverse-event report does not prove the drug caused the event, and FDA says other factors may have contributed. FDA also says reporting from state-licensed pharmacies is likely incomplete. But more than 1,720 reports is not nothing, and you should know it exists.

Another thing on Oak's site that's out of date

Oak's comparison chart marks brand-name medications as having “Frequent shortages” and Oak as “Always In Stock.”

The national shortages that opened the mass-compounding window have ended. FDA confirmed tirzepatide's shortage was resolved in December 2024 and semaglutide's in February 2025. Local backorders can still happen, and we did not test Oak's stock. But Oak's chart does not reflect the current national shortage status.

It matters more than a nitpick, because shortage status changes the legal rules for making products that are essentially copies of approved drugs.

Could Oak's compounded GLP-1 access change after you start?

Yes, access could change — but the pending rule has a narrow scope. FDA proposed on April 30, 2026 to keep semaglutide, tirzepatide, and liraglutide off the 503B Bulks List after finding no clinical need for outsourcing facilities to compound them from bulk substances. The comment period closed July 30, 2026. We found no final determination posted as of August 27, 2026. The proposal directly targets a 503B bulk-compounding pathway; it is not a blanket ban on every patient-specific 503A prescription.

This is the most important forward-looking fact on this page, and we haven't found another Oak review that explains the scope clearly.

Here's the short history:

• 2022: Demand exploded, and semaglutide and tirzepatide were placed on FDA's shortage list.
• During a shortage: Some federal restrictions on compounding products that are essentially copies are relaxed. A shortage is not a free pass from every compounding rule.
• December 19, 2024: FDA confirmed the tirzepatide injection shortage was resolved.
• February 21, 2025: FDA confirmed the semaglutide injection shortage was resolved.
• 2025: FDA's temporary enforcement-discretion periods ended — for tirzepatide, February 18 for 503A and March 19 for 503B; for semaglutide, April 22 for 503A and May 22 for 503B.
• April 30, 2026: FDA proposed not adding semaglutide, tirzepatide, or liraglutide to the 503B Bulks List because it found no clinical need for outsourcing facilities to compound them from bulk drug substances.
• July 30, 2026: The extended public-comment period closed.
• August 27, 2026: We found no final decision posted in the docket or on FDA's announcement page.

The sentence every Oak customer should read

For the 503B proposal, FDA said cost, convenience, and temporary backorders are not the “clinical need” test the law asks it to use.

There is a separate rule for patient-specific 503A compounding. FDA guidance says a compounded product is not treated as an essentially identical copy when a prescriber documents a change that makes a significant difference for that identified patient. Lower price alone is not enough to show that difference.

Read that again. The main reason many people want a compounded GLP-1 — it costs less — does not by itself create the patient-specific difference the 503A rule describes, and it is not the clinical-need basis FDA uses for the pending 503B bulk-list decision.

What this means for you, practically: the risk depends on which pharmacy fills your order, whether it is working under 503A or 503B, what exact formulation it makes, and what patient-specific reason the prescriber documents. Oak does not publish those answers on its weight-loss page.

If you start a compounded GLP-1 today, there is a real chance the pharmacy, formulation, price, or treatment path could change. That does not mean your medication disappears tomorrow. It means you should know your Plan B before you need one.

Ask your prescriber now:

1. What FDA-approved option would we use if this compounded product became unavailable?
2. Would switching require a new titration schedule?
3. What gap between doses would you want me to avoid?
4. What would the replacement cost through insurance or manufacturer self-pay?

That's not a reason to panic. It's a reason to know what comes next.

Who actually owns Oak Longevity?

Oak's own published documents use several company names, and the Terms of Use page still contains two complete sets of terms — one effective December 30, 2025 and another revised July 29, 2026. The newer set names Oaklovesyou LLC. Oak's own site does not clearly identify a founder or CEO. The BBB profile adds facts the site leaves out: it lists Varun Pulapaka under business management, principal contacts, and customer contacts; gives a November 21, 2023 business start date; and gives Oak an A rating while stating it is not BBB accredited.

We read the whole terms document. What we found was unusual.

Two sets of terms, one page

Both sets are live on the same URL right now. Scroll to the bottom of the first set and the second one starts.

The company names Oak uses

Across Oak's current published pages and policies, we found these names:

1. Leaf Longevity Holdings Corp. DBA Oak Longevity
2. Oak Longevity Holdings Corp.
3. Oak Longevity Corp.
4. Oaklovesyou LLC
5. Flow Longevity Holdings Corp.
6. Mito Health Holdings Corp.

The privacy policy also says Oak Longevity Holdings Corp. operates multiple brands, including Oak Longevity, RetaClinic, Mito Health Holdings Corp., and Flow Longevity, and says information collected under one brand may be shared across those brands for purposes described in the policy.

Unfilled template placeholders in the newer terms

The July 2026 terms still contain literal placeholders. They tell customers to contact:

• [INSERT CUSTOMER SERVICE EMAIL] in several sections
• [INSERT CUSTOMER SERVICE ADDRESS] in the copyright section

One help line includes the real [email protected] address and then the placeholder beside it. The document still tells you to email an unfinished template field.

And a contradiction about your phone number

The July 2026 SMS terms say text-message opt-in information will not be shared with third parties or affiliates for marketing or promotional purposes.

Oak's homepage says that giving your number means you consent to marketing messages from Oak Longevity Holdings Corp., Flow Longevity Holdings Corp., and Mito Health Holdings Corp. across affiliated brands and services.

Oak's privacy policy also says information may be shared across Oak's listed brands.

Those statements need a cleaner explanation. Before entering your number, read both the homepage consent and the privacy policy, not only the SMS paragraph.

Where is this company?

Oak's own site does not clearly identify an executive or founding date, but the BBB profile does identify a management contact and business dates.

What the RetaClinic connection does — and does not — prove

Oak's older terms and current privacy policy link Oak with RetaClinic as part of the same brand group. The privacy policy says information collected under one listed brand may be shared across the brands for the purposes in that policy.

That connection is worth knowing if you care how your data moves across affiliated services. It does not prove that Oak and RetaClinic use the same prescriber, pharmacy, medication, or checkout terms for every order.

Something Oak does better than almost anyone

We'll end this section with genuine credit, because it's earned.

Oak's older terms disclose the provider's contracted consult amounts: $40 for a synchronous video visit and $20 for an asynchronous review. That is unusually specific for a telehealth terms page.

Take that for what it is. It tells you the contracted clinical-review amount. It does not tell you the pharmacy cost, Oak's margin, or whether that fee is charged once or inside each renewal. It's a company being unusually open about one part of its economics while being unusually confusing about its own names and documents.

What states does Oak serve?

Oak does not publish one current state list. The older Terms of Use say 45 states. The newer terms say only “certain states.” Oak's terms point readers to an FAQ for availability, but the homepage and weight-loss FAQ do not provide the promised list. Until Oak publishes it, the only reliable answer is the state and product check inside the intake flow.

Here's the conflict, stated exactly:

• Older Oak Terms of Use: services in 45 states, subject to state laws and product limits.
• Newer Oak Terms of Use: services only in “certain states.”
• Oak's public FAQ: no complete state list.
• One affiliate page ranking for this term: claims all 50 states.

What to do: enter your state on the first intake screen, before you invest time in the questionnaire. Then ask two separate questions: “Is the clinician licensed in my state?” and “Can this specific medication from this specific pharmacy be shipped to my state?” Those are not the same check.

The 10 things to check before you pay Oak

Before you enter payment information, you should be able to answer these ten questions from your actual checkout screen, your clinician, and Oak's terms — not from an ad or a review page. If any answer is unclear, stop before a clinician approves the order, because that's when your stated refund window can close.

Print this. Fill it in. It takes ten minutes and it's the single most useful thing on this page.

1. What exact medication and formulation am I getting?
2. Is it compounded, or is it FDA-approved?
3. What is the total charge today — not the “per month” number?
4. How many weeks does that charge cover?
5. Does it renew automatically, and when is the next charge?
6. Can the price go up if my dose changes?
7. Who is my prescriber, and are they licensed in my state?
8. Which pharmacy will actually fill it, and is it 503A or 503B?
9. What exact event makes my order non-refundable?
10. How do I stop both the prescription renewal and any account billing?

And four for the household:

• Does it need refrigeration, and who is home when it arrives?
• Is the packaging child-resistant? Oak's terms say Oak Pharmacy Network prescriptions will not be.
• Can I get an itemized receipt for an HSA or FSA claim?
• What do I do if the box shows up warm, the seal is broken, or the label looks wrong?

If Oak's support answers all fourteen clearly, that tells you something good. If they don't, that tells you something too.

Who is Oak best for — and who should choose a different treatment path?

Oak makes the most sense for a specific person: an adult paying cash who wants a weekly compounded injection, does not plan to bill insurance through the provider, accepts that compounded drugs are not FDA-approved, and is willing to verify the final price, prescriber, pharmacy, renewal, and refund cutoff before paying. Anyone seeking an FDA-approved product, a public dose-by-dose price, insurance help, or a broad refund window should start with a different path.

Let's sort you.

Oak may genuinely be a good call if…

• You're paying cash and cost is the deciding factor
• You want the weekly compounded injection, where Oak's public starting price can be lower than current manufacturer cash prices for approved pens
• You care about the complete all-in price more than whether Oak labels part of it a membership fee
• You don't want a required video visit and are comfortable with asynchronous review if the clinician allows it
• You're willing to do the fourteen checks above
• You understand what compounded means and you're okay with it

If that's you, check Oak's current price and availability in your state → (tracked Oak link — we may earn a commission)

Choose something else if…

You want semaglutide in an FDA-approved pill. Wegovy tablets have a published FDA label and a public dose-by-dose NovoCare price. The starter dose is $149, but the standard labeled first-year cash path is about $3,338 under today's prices. Compare that full path with Oak's exact oral cart — not Oak's general $190 headline and not the $149 starter headline alone.

You might have insurance coverage. Don't pay cash until you know. Eligible commercial coverage and manufacturer savings can lower the patient cost, but $25 is not guaranteed and program limits apply. Ro's free checker can tell you what your insurer says about the Ozempic pen, Wegovy pen, or Zepbound pen before you enroll in care. Check your coverage free →

You want compounded treatment, but Oak's price uncertainty is a dealbreaker. Fair. Use our matching tool to compare current cash-pay paths by state, formulation, published medication price, membership cost, dose-based pricing, and cancellation setup. Compare cash-pay options →

You're needle-averse. The FDA-approved Wegovy tablet is the clearest non-injection option on this page. Do not treat a compounded “oral,” “sublingual,” “troche,” or “gum” product as the same medication just because the marketing uses the words GLP-1 or semaglutide.

You want an in-person doctor, a guaranteed yearly price, or a broad refund window. None of those describe Oak's public offer. Take our quiz and choose a path that does.

Still not sure which bucket you're in? That's the most common situation, and it's fine. Get your personalized GLP-1 path in 60 seconds →

Our verdict on Oak

Oak is not an automatic yes, and it's not an automatic no. It is a functioning cash-pay telehealth platform with a potentially real price advantage on weekly compounded injections and a real transparency problem around public pricing, recurring billing, state availability, and corporate documents. For a cash-paying adult who wants the shot and takes ten minutes to verify the final cart, pharmacy, and terms, Oak can be a reasonable option. For someone who wants an FDA-approved drug, insurance help, or a fixed public dose ladder, better-documented paths exist.

Here's our honest read after going through every page Oak publishes.

What Oak gets right: low public starting prices; free shipping and care-team access as advertised; an asynchronous option; Trustpilot reviews with no recent history of company invitations; individual reviewers who report quick human support; and an unusually specific disclosure of the clinician's contracted consult amount.

What we can't get past: you shouldn't have to open three pages of a company's own website to find three different starting prices. A “no hidden membership fee” claim should not sit beside live terms that call part of checkout a membership fee. The terms page should not have two contracts stacked on it with different company names and unfinished contact placeholders. And a reader should not have to begin intake to learn whether the exact state, drug, and pharmacy combination is available.

The thing that would change our mind: publish one current price table by medication, form, dose, first charge, renewal charge, and plan length. Name the pharmacy network and explain when a different pharmacy may fill the order. Post the state-by-product list the terms point to. Replace the two contracts with one clean operative version. None of that is hard, and all of it would move Oak up considerably.

Where we land: for a weekly compounded injection paid in cash, Oak is competitive enough to check — as long as you save the final cart and verify the prescriber, pharmacy, dose, renewal, and refund cutoff before approval. For an FDA-approved pill or pen, or when coverage may exist, compare the complete approved-drug path first. The current manufacturer cash prices are far below the $1,000–$1,400 frame on Oak's comparison chart, even though the Wegovy pill is not $149 at every dose.

Check Oak's current eligibility, price, and order terms → (tracked Oak link — we may earn a commission)

Prescription required. Approval is not guaranteed. Save your final cart and confirm the pharmacy, renewal terms, dose-based price changes, and refund cutoff before you pay.

Oak GLP-1 reviews: frequently asked questions

Is Oak Longevity legit?

Yes. Oak is a functioning telehealth platform with published terms, a working phone line, a BBB profile, contracted medical-review and pharmacy fulfillment relationships, and a live intake flow. That does not mean its compounded products are FDA-approved, its public starting price is your final price, or a refund remains available after approval and pharmacy transfer. Verify the prescriber, pharmacy, product, total charge, renewal, and refund cutoff before paying.

How much does Oak GLP-1 cost per month?

Oak published three live starting-price claims on August 27, 2026: $119 on its homepage, $167 on an older live home page, and $190 on its weight-loss page. The $119 claim covers “programs” and may not be a GLP-1 price. One Trustpilot reviewer reported paying $190 and then $229 as her dose increased. Oak's terms say the fee can change with dosage, prescription, or product form. Your final cart is the only current price that belongs to you.

Does Oak charge a membership fee?

Oak's weight-loss page says “no hidden membership fees.” An older set of terms still live on the same URL says checkout includes a membership fee tied to the provider consult and lists a $40 synchronous or $20 asynchronous contracted clinician amount. We could not reconcile those two statements. Judge the complete charge, not the label: confirm today's total, what medication it includes, and what renews.

Is Oak a subscription?

Oak's terms say most prescriptions are configured to renew and charge the payment method on file until a stopping event occurs. Some checkout material uses “No Subscriptions,” which may mean no separate access plan on that offer. It does not cancel the recurring-prescription language in Oak's terms. Read the renewal line on your own cart.

Can I cancel Oak and get a refund?

You can ask to stop future renewals. Oak's terms say an approved treatment becomes non-refundable after the order is sent to the pharmacy or fulfillment partner, even if the customer later tries to stop, hold, reroute, return, or cancel shipment. Oak handles cancellation on a best-efforts basis, and a paid refill within 48 hours of shipment may still go out. Cancel early and get written confirmation of both the prescription and account billing status.

Are Oak's compounded GLP-1 medications FDA-approved?

No. Compounded drugs are not FDA-approved finished drug products. FDA does not review them for safety, effectiveness, or quality before marketing, and they are not FDA-approved generics or FDA-reviewed equivalents of Wegovy, Ozempic, Zepbound, or Mounjaro.

Does Oak use the same active ingredient as Wegovy or Zepbound?

Oak uses “same active ingredient” and “identical” molecule language on its site. FDA says companies should not market non-FDA-approved compounded GLP-1 drugs as generic versions of, the same as, or clinically proven to match approved products. Ask for the exact ingredient form, pharmacy, concentration, and label. Do not treat marketing equivalence as FDA-reviewed equivalence.

Is Oak cheaper than Wegovy?

It depends on the form and dose. The Wegovy pill starts at $149, but its standard FDA-labeled dose ladder costs about $3,338 in the first year under NovoCare's current published prices. Oak examples at a flat $190 or $229 a month would total $2,280 or $2,748, but Oak's terms allow price changes and Oak does not publish a pill-specific ladder. The Wegovy pen example is $3,888 for a new patient eligible for two $199 fills and ten $349 fills. Oak can be cheaper on a compounded injection, but the exact difference needs your final cart.

What does the $149 Wegovy pill price actually cover?

NovoCare lists the 1.5 mg starter tablet at $149. The FDA label then steps to 4 mg, 9 mg, and a recommended 25 mg maintenance dose. NovoCare's standard prices are $199 for 4 mg and $299 for 9 mg and 25 mg. A temporary $149 offer for the 4 mg tablet ends August 31, 2026. The $149 headline is not the standard price for every month of treatment.

Does Oak's price go up when the dose goes up?

It can. Oak's terms say the subscription fee may change with dosage, prescription, or product form. One five-star Trustpilot reviewer reported moving from $190 to $229 as her dose increased. Ask support for the price at every planned dose before your first order.

Does Oak take insurance?

Oak describes its services as cash pay. Its terms say Oak and its medical group do not work with commercial insurance and will not submit claims to Medicare or Medicaid. That does not mean your health plan has no GLP-1 benefit elsewhere. Check coverage before you commit to cash pay.

Can I use an HSA or FSA card with Oak?

Oak's terms put responsibility on the customer to confirm HSA or FSA eligibility and do not guarantee it. Ask your plan administrator before paying, confirm the exact product and service are eligible, and request an itemized receipt. Card acceptance alone does not prove the expense is eligible.

What pharmacy does Oak Longevity use?

Oak checkout material names InnovaScript Pharmacy as a preferred pharmacy and NVP Medical Group as a contracted medical group. Oak's terms describe a broader Oak Pharmacy Network, so a preferred pharmacy is not proof that it will fill your order. Ask for the actual dispensing or compounding pharmacy before approval and verify its license through the relevant state board.

Is Oak available in all 50 states?

Oak does not publish one current answer. Its older live terms say 45 states. Its newer terms say “certain states.” The FAQ does not provide the promised state list. Enter your state at the first intake screen and confirm both clinician licensure and product shipping for that state.

Who owns Oak Longevity?

Oak's published pages use several entity names, including Leaf Longevity Holdings Corp., Oak Longevity Holdings Corp., Oak Longevity Corp., and Oaklovesyou LLC. The privacy policy also names Flow Longevity Holdings Corp. and Mito Health Holdings Corp. The BBB profile lists Varun Pulapaka under business management and gives a November 21, 2023 start date and June 17, 2024 incorporation date. Oak's site still needs a cleaner plain-English ownership page.

Does Oak medication arrive in child-resistant packaging?

Oak's newer terms say prescriptions filled through the Oak Pharmacy Network will not be shipped in child-resistant packaging. If there are children or vulnerable adults in the home, arrange secure storage before delivery. Follow the pharmacy label for refrigeration and storage limits.

What happens if my Oak shipment arrives warm?

Do not guess. Photograph the unopened box, ice packs, medication label, seal, and delivery time. Contact both Oak and the dispensing pharmacy before using it. Follow the pharmacy's written answer and the product label because allowed room-temperature time can differ by product. FDA has received complaints about compounded injectable GLP-1 drugs arriving warm or with too little ice.

What happens if FDA finalizes the 503B proposal?

The pending proposal concerns whether 503B outsourcing facilities may use bulk semaglutide, tirzepatide, or liraglutide under the clinical-need list. Comments closed July 30, 2026, and we found no final determination posted by August 27. A final exclusion could change some 503B supply paths, but it would not by itself erase every patient-specific 503A prescription. The effect on one Oak customer depends on the actual pharmacy, legal pathway, ingredient, formulation, and documented patient need.

How we researched this page

We read Oak's homepage, weight-loss page, older live home page, privacy policy, and both complete sets of Terms of Use on the same terms URL. We checked the public intake and crawlable checkout material for named care and pharmacy partners. We reviewed Oak's Trustpilot profile, counted the displayed reviews and recent reviews, checked the star split and company-activity summary, and read the cited individual reviews. We opened Oak's Better Business Bureau profile.

We checked Wegovy prices against NovoCare and the tablet schedule against FDA-approved prescribing information. We checked Zepbound self-pay terms against LillyDirect and Ro's current checker and membership claims against Ro's own pages. We checked every compounding and regulatory claim against FDA pages, FDA guidance, FDA press releases, and the Federal Register.

We also opened the third-party page making the 75,000-review claim and compared its numbers, state claim, product list, testimonials, and scoring table with the named sources.

We did not purchase medication, test its contents, complete a cancellation, time shipping or support, receive care through Oak, or verify which pharmacy would fill a specific reader's prescription. Where the public evidence could not support a current claim, we removed it or narrowed it.

We may earn a commission from Oak links and from some other providers that may appear elsewhere on The RX Index. That is why the page shows the math, source dates, and damaging facts instead of asking you to trust a recommendation.

Spot something wrong? Tell us and we'll verify it, correct it, and date the change.

Update log

Next scheduled check: September 1, 2026, after NovoCare's temporary $149 offer for the 4 mg Wegovy tablet ends August 31.

Sources

Oak's published material

• Oak homepage — $119 programs claim, patient and member counts, marketing consent
• Oak weight-loss page — $190 starting price, product types, “no hidden membership fees,” comparison claims
• Oak older live home page — $167 starting price
• Oak Terms of Use — both live versions, renewal, pricing, refund, cancellation, entities, state language, packaging, arbitration
• Oak privacy policy — affiliated brands and information sharing
• Oak checkout FAQ — preferred pharmacy, medical group, and billing language
• Oak intake

Reviews and business records

• Trustpilot — Oak Longevity
• Better Business Bureau — Oak Longevity
• Third-party page making the 75,000-review claim

FDA-approved medication pricing and labels

• NovoCare Pharmacy — Wegovy tablet and pen self-pay prices
• FDA-approved Wegovy prescribing information — tablet dose escalation
• LillyDirect — Zepbound self-pay pricing and refill terms
• Ro — free GLP-1 insurance coverage checker
• Ro — Body program pricing

FDA, Federal Register, and FTC

• FDA's concerns with unapproved GLP-1 drugs used for weight loss
• FDA statement on misleading marketing of non-FDA-approved GLP-1 drugs — February 6, 2026
• FDA warning letters to 30 telehealth companies — March 3, 2026
• FDA policies after national GLP-1 shortages stabilized
• FDA guidance on 503A drugs that are essentially copies
• FDA comparison of sections 503A and 503B
• FDA BeSafeRx state-license checker
• Federal Register — May 1, 2026 proposed 503B bulk-list determination
• Federal Register — June 26, 2026 extension through July 30
• FTC Consumer Reviews and Testimonials Rule Q&A

All sources were accessed or rechecked August 27, 2026 unless a different date is stated.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz.

We'll ask about your state, insurance, whether you want an FDA-approved or compounded medication, your preferred treatment form, and your budget — then show you paths that fit, with source-verified pricing and the billing details that change the answer.

Find My GLP-1 Path →

This article is for general information only. It is not medical advice, a diagnosis, a treatment recommendation, or a guarantee of prescription approval, medication availability, insurance coverage, price, or any clinical outcome. Prescription decisions are made by licensed clinicians. Compounded medications are not FDA-approved finished drug products. Individual results vary. Talk to a qualified healthcare professional before starting, changing, or stopping any prescription treatment.